Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer

Table 2 Patient characteristics

Characteristic	n	%
Age in yr, median (range)	53 (24-71)
Men	28	70.0
Tumor size in cm, median (range)	5.0 (2-20)
Location of primary tumor
Upper 1/3rd of stomach	8	20
Middle 1/3rd of stomach	8	20
Lower 1/3rd of stomach	14	35
≥ 2 sites involved	10	25
Surgery type
Partial gastrectomy	36	90
Total gastrectomy	4	10
Positive LNs, median (range)	7 (1-26)
LNs resected, median (range)	24 (15-56)
LN ratio, median (range)	0.27 (0-0.86)
Extent of dissection
D1	18	45
D2	22	55
Lauren type
Intestinal type	12	30
Diffuse type	16	40
Mixed type	12	30
Tumor differentiation
Good	1	2.5
Moderate	8	20
Poor	31	77.5
Lymphatic/vascular invasion
Absent	16	40
Present	24	60
Perineural invasion
Absent	30	75
Present	10	25
Signet ring cells
Absent	29	72.5
Present	11	27.5
Tumor deposit
Absent	34	85
Present	6	15
Stage (AJCC 7th)
IIa	2	5
IIb	6	15
IIIa	11	27.5
IIIb	11	27.5
IIIc	10	25
Stage (AJCC 6th)
Ib	2	5
II	14	35
IIIa	10	25
IIIb	2	5
IV	12	30

AJCC: American Joint Committee on Cancer; LN: Lymph node.